Lymphoblastic Lymphoma
📧 Sign up to get email alerts when something new happens for Lymphoblastic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Study of PD5K3 in Healthy Adult Volunteers [Phase 1]
Phase 1 clinical trial update for PD5K3 in healthy adult volunteers; the study has completed and investigated safety and pharmacokinetics. C…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: BeFluBu vs FluBuRux Conditioning in Haploidentical HCT [Phase 2]
Phase 2 clinical trial comparing BeFluBu vs FluBuRux conditioning regimens in haploidentical stem cell transplantation is currently recruiti…
-
CLINICAL_TRIALS withdrawal · 2024-06-21Clinical Trial Update: HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]
Clinical trial update notes the withdrawal of a Phase 1/2 study evaluating decitabine with venetoclax and navitoclax for relapsed or refract…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) [Phase 2]
This Phase 2 clinical trial update reports on conditioning with benadamustine, fludarabine, and busulfan (FluBuBe) for recipients of haploid…
-
CLINICAL_TRIALS other · 2024-05-06Clinical Trial Update: Expanded Access to Navitoclax
Expanded access program for Navitoclax sponsored by AbbVie for myelofibrosis, acute lymphoblastic leukemia, and lymphoblastic lymphoma is no…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2023-11-29FDA Approved: ASPARLAS — Supplemental Application (Servier Pharmaceuticals LLC)
FDA approved a supplemental application for ASPARLAS (calaspargase pegol) from Servier Pharmaceuticals LLC, resulting in changes to the prod…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) [Phase 2, Phase 3]
Open-label study of JZP-458 (RC-P) in acute lymphoblastic leukemia and lymphoblastic lymphoma completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma [Phase 2]
Phase 2 trial investigating BL-8040 with nelarabine for relapsed/refractory T-ALL and T-ALL/LBL was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
Phase 2 study evaluating daratumumab for relapsed/refractory precursor B-cell or T-cell acute lymphoblastic leukemia and lymphoblastic lymph…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma [Phase 1]
Phase 1 trial evaluating temsirolimus with etoposide and cyclophosphamide in children with relapsed acute lymphoblastic leukemia and non-Hod…
-
FDA approval · 2023-06-15FDA Approved: CYTARABINE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for Cytarabine from Meitheal Pharmaceuticals Inc., completing a modification to the existing Cytarab…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL [Phase 2]
Phase 2 clinical trial evaluating a Modified TBF conditioning regimen before allogeneic stem cell transplant in T-ALL/LBL.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating mitoxantrone with clofarabine for recurrent non-Hodgkin lymphoma or acute leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating a fludarabine and total body irradiation regimen as conditioning for allogeneic hematopoietic cell transpl…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma [Phase 2]
This Phase 2 trial compares SC-PEG Asparaginase to Oncaspar in pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma, with resul…
-
CLINICAL_TRIALS trial_result · 2022-08-19Clinical Trial Update: Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults [Phase 4]
Phase 4 clinical trial update for newly diagnosed mature B-ALL, Burkitt's lymphoma, and other high-grade lymphomas in adults has completed.
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
Phase 2 trial evaluating a multi-agent regimen (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for Acute Lymphoblastic L…
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma [Phase 2]
Phase 2 trial update for newly diagnosed lymphoblastic lymphoma (adult/child) completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma [Phase 1, Phase 2]
Phase 1 and Phase 2 trial update for ruxolitinib and chidamide in acute T cell lymphoblast leukemia/lymphoblastic lymphoma ongoing; current …
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy [Phase 2]
Phase 2 trial update on intravenous Erwinaze for patients with allergy to frontline asparaginase therapy in acute lymphoblastic leukemia or …
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy and Ofatumumab in adults with acute lymphoblastic leukemia or lymphoblastic lymphoma compl…
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.
-
CLINICAL_TRIALS trial_result · 2020-04-15Clinical Trial Update: Thiopurine EnhAnced Maintenance Therapy [Phase 1, Phase 2]
Phase 1/2 trial evaluating thiopurine enhanced maintenance therapy in acute lymphoblastic leukemia and lymphoblastic lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults [Phase 2]
Phase 2 trial evaluating four-drug reinduction with bortezomib for relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymp…